-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Downgrades Blueprint Medicines to Equal-Weight, Lowers Price Target to $129

Benzinga·06/18/2025 12:50:52
Listen to the news
Wells Fargo analyst Derek Archila downgrades Blueprint Medicines (NASDAQ:BPMC) from Overweight to Equal-Weight and lowers the price target from $143 to $129.